Hemab Therapeutics Holdings, Inc. COAG
Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) is a hematology drug developer. Its lead program, sutacimig (HMB-001), is in Phase 2 for Glanzmann thrombasthenia (Phase 1/2) and Factor VII deficiency (Phase 2), prophylaxis. Its next catalyst on record is sutacimig (Glanzmann thrombasthenia): commence Phase 3 trial (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: sutacimig (Glanzmann thrombasthenia) — commence Phase 3 trial (H2 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| sutacimig (HMB-001) | Glanzmann thrombasthenia (Phase 1/2, Part C long-term extension ongoing) | antibody | Phase 2 |
| sutacimig (HMB-001) | Factor VII deficiency (Phase 2) | antibody | Phase 2 |
| HMB-002 | Von Willebrand Disease (Phase 1/2 Velora Pioneer) | antibody | Phase 1 |
| HMB-003 | heavy menstrual bleeding (anti-fibrinolytic, plasmin inhibition) | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.